Reneo Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Reneo Pharmaceuticals's earnings have been declining at an average annual rate of -30.4%, while the Biotechs industry saw earnings growing at 19.7% annually.
Key information
-30.4%
Earnings growth rate
41.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -73.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Oct 03
Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth
Apr 25Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Nov 22We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Aug 09Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Apr 22We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth
Jan 20Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation
Oct 02Our First Look At Reneo Pharmaceuticals
Aug 15Revenue & Expenses Breakdown
How Reneo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -57 | 24 | 37 |
| 31 Mar 24 | 0 | -71 | 25 | 51 |
| 31 Dec 23 | 0 | -77 | 26 | 57 |
| 30 Sep 23 | 0 | -67 | 23 | 49 |
| 30 Jun 23 | 0 | -61 | 20 | 46 |
| 31 Mar 23 | 0 | -54 | 18 | 39 |
| 31 Dec 22 | 0 | -52 | 16 | 38 |
| 30 Sep 22 | 0 | -49 | 15 | 34 |
| 30 Jun 22 | 0 | -49 | 15 | 34 |
| 31 Mar 22 | 0 | -46 | 14 | 32 |
| 31 Dec 21 | 0 | -40 | 12 | 28 |
| 30 Sep 21 | 0 | -35 | 9 | 26 |
| 30 Jun 21 | 0 | -28 | 6 | 21 |
| 31 Mar 21 | 0 | -22 | 4 | 18 |
| 31 Dec 20 | 0 | -19 | 4 | 16 |
Quality Earnings: RPHM is currently unprofitable.
Growing Profit Margin: RPHM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RPHM is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare RPHM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RPHM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: RPHM has a negative Return on Equity (-73.55%), as it is currently unprofitable.